AllSci News
Takeda adds Japan approval for narcolepsy treatment Orzeyful
Japan's Ministry of Health, Labour and Welfare (MHLW) has approved Orzeyful (oveporexton) for the treatment of narcolepsy type 1 (NT1) in adults, marking a...
Trodelvy stakes out broader first-line TNBC role with EU combo approval
The European Commission has approved Trodelvy (sacituzumab govitecan) in combination with pembrolizumab for adult patients with unresectable locally...
AZ, Daiichi Sankyo take Datroway-rilvegostomig combo into Phase III bladder cancer trial
The first Phase III adjuvant trial of rilvegostomig, AstraZeneca's anti-PD-1/TIGIT bispecific antibody, in urothelial cancer has enrolled its first patient...
Spyre’s TL1A antibody hits RA endpoint but falls short in Phase II
SPY072, Spyre Therapeutics' (Nasdaq: SYRE) extended half-life anti-TL1A antibody, produced statistically significant reductions in disease activity in...
Viiv's dolutegravir nodded by FDA for HIV treatment in newborns
The US FDA has approved Tivicay PD (dolutegravir) tablets for oral suspension to treat HIV infection in newborns from birth up to four weeks of age weighing...
Akeso’s ivonescimab tops Imfinzi in fifth straight positive Phase III readout
A randomized Phase III trial in China has produced the first known overall survival superiority result over an anti-PD-(L)1 plus chemotherapy regimen in...
SK Bio taps up Biohaven for Kv7 platform and epilepsy drug in USD 795m deal
SK Biopharmaceuticals has agreed to acquire an exclusive worldwide license to Biohaven Ltd.'s (NYSE: BHVN) Kv7 ion channel platform, including lead asset...
4basebio and Genezen integrate synthetic DNA platform into viral vector manufacturing workflow
UK-based 4basebio PLC (AIM: 4BB) and Indianapolis-based Genezen, a gene therapy contract development and manufacturing organization (CDMO), announced a...
Ziihera moves into first-line HER2+ gastroesophageal cancer with FDA approval
The US FDA has approved two regimens containing Ziihera (zanidatamab-hrii) for the first-line treatment of adults with unresectable locally advanced or...
Ivonescimab Phase III PFS benefit gets peer-reviewed backing ahead of FDA decision
Publication of the global Phase III HARMONi trial data in The Lancet Oncology gives ivonescimab its first peer-reviewed, globally conducted evidence base...
ARCH, Population Health launch Sentivera around Haisco immunology asset in USD 1.5b deal
China-based Haisco Pharmaceutical Group (SZSE: 002653) has licensed a preclinical immunology asset to Sentivera, a newly formed US venture co-founded by...
Revier launches with EUR 6m bet on selective HDAC inhibition
Heidelberg, Germany-based Revier Therapeutics has closed a EUR 6 million seed financing round to advance a preclinical pipeline of selective class IIa...
Airway Therapeutics raises USD 50m to advance late-stage zelpultide alfa trial in BPD
Atlanta-based Airway Therapeutics, Inc. has closed a USD 50 million equity round to fund the late-stage clinical development of zelpultide alfa, a...
EMA rejects arimoclomol for Niemann-Pick disease type C over efficacy concerns
The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) issued a negative opinion on July 23, 2026, recommending refusal of...
CSPC's RSV vaccine clears FDA for US trials weeks after China approval
SYS6057, a recombinant respiratory syncytial virus (RSV) vaccine candidate developed by CSPC Pharmaceutical Group (HKEX: 01093), has received FDA clearance...
The AllSci Brief
Free, systematic R&D and deal news. Daily.